1
|
Volpe A, Racioppi M, D'Agostino D, Cappa E, Gardi M, Totaro A, Pinto F, Sacco E, Marangi F, Palermo G, Bassi P. Bladder Tumor Markers: A Review of the Literature. Int J Biol Markers 2018; 23:249-61. [DOI: 10.1177/172460080802300409] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Bladder cancer is among the top eight most frequent cancers. Its natural history is related to a combination of factors that impact on its aggressiveness. Cystoscopy and urine cytology are the currently used techniques for the diagnosis and surveillance of non-invasive bladder tumors. The sensitivity of urine cytology for diagnosis is not high, particularly in low-grade tumors. The combination of voided urine cytology and new diagnostic urine tests would be ideal for the diagnosis and follow-up of bladder cancer. However, in order to have some clinical utility, new diagnostic and/or prognostic markers should achieve better predictive capacity that the currently used diagnostic tools. None of the markers evaluated over the last years showed remarkable sensitivity or specificity for the identification of any of the diverse types of bladder cancer in clinical practice. The limitations of the known prognostic markers have led to the research of new molecular markers for early detection of bladder cancer. This research focused in particular on the discovery of biomarkers capable of reducing the need for periodic cystoscopies or, ideally, offering a non-invasive examination instead. In this review, we will examine various new markers of bladder cancer and their value in the diagnosis and follow-up of non-muscle-invasive bladder cancer. When compared with urine cytology, which showed the highest specificity, most of these markers demonstrated an increased sensitivity.
Collapse
Affiliation(s)
- A. Volpe
- Department of Urology, The Catholic University School of Medicine, Rome - Italy
| | - M. Racioppi
- Department of Urology, The Catholic University School of Medicine, Rome - Italy
| | - D. D'Agostino
- Department of Urology, The Catholic University School of Medicine, Rome - Italy
| | - E. Cappa
- Department of Urology, The Catholic University School of Medicine, Rome - Italy
| | - M. Gardi
- Department of Urology, The Catholic University School of Medicine, Rome - Italy
| | - A. Totaro
- Department of Urology, The Catholic University School of Medicine, Rome - Italy
| | - F. Pinto
- Department of Urology, The Catholic University School of Medicine, Rome - Italy
| | - E. Sacco
- Department of Urology, The Catholic University School of Medicine, Rome - Italy
| | - F. Marangi
- Department of Urology, The Catholic University School of Medicine, Rome - Italy
| | - G. Palermo
- Department of Urology, The Catholic University School of Medicine, Rome - Italy
| | - P.F. Bassi
- Department of Urology, The Catholic University School of Medicine, Rome - Italy
| |
Collapse
|
2
|
Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, Grusing S, Selph S. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis. Ann Intern Med 2015; 163:922-31. [PMID: 26501851 DOI: 10.7326/m15-0997] [Citation(s) in RCA: 152] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Urinary biomarkers may be a useful alternative or adjunct to cystoscopy for diagnosis of bladder cancer. PURPOSE To systematically review the evidence on the accuracy of urinary biomarkers for diagnosis of bladder cancer in adults who have signs or symptoms of the disease or are undergoing surveillance for recurrent disease. DATA SOURCES Ovid MEDLINE (January 1990 through June 2015), Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and reference lists. STUDY SELECTION 57 studies that evaluated the diagnostic accuracy of quantitative or qualitative nuclear matrix protein 22 (NMP22), qualitative or quantitative bladder tumor antigen (BTA), fluorescence in situ hybridization (FISH), fluorescent immunohistochemistry (ImmunoCyt [Scimedx]), and Cxbladder (Pacific Edge Diagnostics USA) using cystoscopy and histopathology as the reference standard met inclusion criteria. Case-control studies were excluded. DATA EXTRACTION Dual extraction and quality assessment of individual studies. Overall strength of evidence (SOE) was also assessed. DATA SYNTHESIS Across biomarkers, sensitivities ranged from 0.57 to 0.82 and specificities ranged from 0.74 to 0.88. Positive likelihood ratios ranged from 2.52 to 5.53, and negative likelihood ratios ranged from 0.21 to 0.48 (moderate SOE for quantitative NMP22, qualitative BTA, FISH, and ImmunoCyt; low SOE for others). For some biomarkers, sensitivity was higher for initial diagnosis of bladder cancer than for diagnosis of recurrence. Sensitivity increased with higher tumor stage or grade. Studies that directly compared the accuracy of quantitative NMP22 and qualitative BTA found no differences in diagnostic accuracy (moderate SOE); head-to-head studies of other biomarkers were limited. Urinary biomarkers plus cytologic evaluation were more sensitive than biomarkers alone but missed about 10% of bladder cancer cases. LIMITATION Restricted to English-language studies; no search for studies published only as abstracts; statistical heterogeneity present in most analyses; few studies for qualitative NMP22, quantitative BTA, and Cxbladder; and methodological shortcomings in almost all studies. CONCLUSION Urinary biomarkers miss a substantial proportion of patients with bladder cancer and are subject to false-positive results in others. Accuracy is poor for low-stage and low-grade tumors. PRIMARY FUNDING SOURCE Agency for Healthcare Research and Quality. (PROSPERO registration number: CRD42014013284).
Collapse
Affiliation(s)
- Roger Chou
- From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington
| | - John L. Gore
- From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington
| | - David Buckley
- From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington
| | - Rongwei Fu
- From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington
| | - Katie Gustafson
- From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington
| | - Jessica C. Griffin
- From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington
| | - Sara Grusing
- From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington
| | - Shelley Selph
- From Oregon Health & Science University, Portland, Oregon, and University of Washington, Seattle, Washington
| |
Collapse
|
3
|
Moatamed NA, Apple SK, Bennett CJ, Aronson WJ, Klisak I, Shirley BJ, Moatamed F. Exclusion of the uniform tetraploid cells significantly improves specificity of the urine FISH assay. Diagn Cytopathol 2011; 41:218-25. [PMID: 21987521 DOI: 10.1002/dc.21831] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2011] [Accepted: 08/09/2011] [Indexed: 11/06/2022]
Abstract
The urine fluorescence in situ hybridization (FISH) assay (UroVysion™), with the current scoring criteria, has a higher sensitivity than routine cytopathology but a lower specificity. Among 215 urine FISH tests we performed, 45 had associated histopathology and clinical follow up. In this study, a cell with four signals for each probe was classified as a uniform tetraploid cell (UTC); a presumed reparative cell which is currently classified as an abnormal cell in the FDA approved assay. By using the existing criteria, the tests were scored as positive or negative before and after exclusion of the UTCs. Before the exclusion, 24 positive, 13 negative, seven false positive, and one false negative result were obtained with 96% sensitivity and 65% specificity. After the exclusion, the results changed to 22 positive, 19 negative, one false positive, and three false negatives resulting in a 88% sensitivity of 88% and a 95% specificity; a significant improvement in the specificity. We conclude that exclusion of the UTCs as abnormal cells would result in a more solid performance of the FISH assay.
Collapse
Affiliation(s)
- Neda A Moatamed
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
| | | | | | | | | | | | | |
Collapse
|
4
|
Evaluation of the Bard BTA-test in the diagnosis of upper urinary tract tumours. ACTA ACUST UNITED AC 2008; 54:19-24. [PMID: 18595223 DOI: 10.2298/aci0704019j] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The BTA-test is an agglutination assay that qualitatively detects the presence of complexes of basement membrane within the urine of patients with bladder cancer. However, the significance of BTA test in other urotelial tumours has not been extensively studied. Therefore, in the present research, we examined the validity of BTA-test in patients suffering from ureteral or renal pelvis cancer, and compare results with urincitology. 35 patients were included in this study (13 with ureteral and 22 with renal pelvis cancer). BTA-test and urincitology in each patient was performed on two urine specimens: morning voiding urine and separate urine. Separate urine was obtained by means of ureteral catheter. The results of BTA test were compared with urine cytology. All patients udervent routine clinical examination (biochemical analysis, ultrasonography, i.v. urography and retrograde urography). The presence of urothelial carcinoma was histopatologically proved in all cases. 35 patients with renal calculosis without malignancy were control group. Separate and voided urine was taken for examination with BTA test and urincitology from all these patients. BTA test in urine specimen obtained by ureteral catheter were positive in 22 (62.9 %) patients and in complete urine in 18 (51,4%) patients. Urine cytology was positive in 20 (57,1%) separate urine specimen and in complete urine in 17 (48.6%) patients. Characteristics of each patient, clinical findings and patohystology findings take places in statistic evaluation of the results. The sensitivity of BTA test depends directly on histopatology characteristics of tumours. Tumours with high grade and high stage more often have positive resuIts of test and urincitology. The test had the highest sensitivity among the group of high risk patients, with T2, T3, T4 stadium, 77,8% in separate urine and 61.11% in voided urine with specificity of 80% for separate urine and 85.71% for voided urine. Sensitivity for cytology in the same group was 72,22% for separate and 55,56% for voided urine, with specificity of 97,14% in both specimens. Based on the obtained results, we can conclude that simple and rapid BTA test can have significant position in the diagnostics of upper urinary tract tumours, but we still have to search for an ideal tumour marker for transitional cell carcinoma of upper urinary tract.
Collapse
|
5
|
Bassi P, De Marco V, De Lisa A, Mancini M, Pinto F, Bertoloni R, Longo F. Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int 2005; 75:193-200. [PMID: 16215303 DOI: 10.1159/000087792] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2004] [Accepted: 02/02/2005] [Indexed: 11/19/2022]
Abstract
Transitional cell carcinoma of the bladder is the second most common malignancy of the genitourinary tract. Cystoscopy and urine cytology are the traditional most used techniques for diagnosis and surveillance of superficial bladder cancer. Urine cytology is specific for diagnosis of bladder cancer but sensitivity results not high, particularly in low-grade disease. Voided urine can be easily obtained and therefore additional diagnostic urine tests would be ideal for screening or follow-up of transitional cell carcinoma. A number of studies have focused on the evaluation of urinary markers that hold promise as non-invasive adjuncts to conventional diagnostic or surveillance techniques. In this review we discuss several new urinary markers (test for bladder tumor antigen, NMP22, fibrin degradation products, telomerase, fluorescence in situ hybridization test, flow cytometry) and their role in detection and follow-up of bladder cancer. Most of these markers have higher sensitivity than urine cytology, but voided urine cytology has the highest specificity.
Collapse
|
6
|
Gaston KE, Pruthi RS. Value of urinary cytology in the diagnosis and management of urinary tract malignancies. Urology 2004; 63:1009-16. [PMID: 15183936 DOI: 10.1016/j.urology.2003.12.004] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2002] [Accepted: 12/02/2003] [Indexed: 10/26/2022]
Affiliation(s)
- Kris E Gaston
- Department of Surgery, Division of Urology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7235, USA
| | | |
Collapse
|
7
|
Eissa S, Kassim S, El-Ahmady O. Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers. Curr Opin Obstet Gynecol 2004; 15:395-403. [PMID: 14501243 DOI: 10.1097/00001703-200310000-00008] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE OF REVIEW Cystoscopy is currently considered the gold standard for the detection of bladder tumours. The role of urine cytology in the initial detection and follow-up of patients is under discussion. Many efforts have been made to increase the detection rates and to predict the outcome of bladder cancer. In this subject review, a series of morphology-based, biochemical and molecular markers were compared with urine cytology for the detection of bladder cancer. RECENT FINDINGS Among the various markers reviewed, the average published sensitivity and specificity for the Bard tumour antigen test was 60 and 77%; for the nuclear matrix protein 22 test it was 67 and 72%; for the hyaluronic acid and hyaluronidase test it was 91 and 84%; for the ImmunoCyt it was 90 and 75%; for fluorescence in-situ hybridization it was 85 and 95%; for the telomerase assay it was 77 and 85%; and for the microsatellite assay it was 89 and 100%. DNA ploidy measurements, recent molecular markers and immunoassays designed to detect keratins, proteins, cell adhesion molecules, fibrinogen degradation products, and fibrinolysis markers were also included. SUMMARY As is clear from the brief summary of available assays, the optimal method of application is not yet clear. The integration of an assay into clinical practice takes more than just the documentation of its sensitivity and specificity. However, several of the procedures have received considerable support from urologists as assisting them in the management of their patients.
Collapse
Affiliation(s)
- Sanaa Eissa
- Oncology Diagnostic Unit, Biochemistry Department, Ain Shams Faculty of Medicine, Cairo, Egypt.
| | | | | |
Collapse
|
8
|
Friedrich MG, Hellstern A, Toma MI, Hammerer P, Huland H. Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence? Eur Urol 2003; 43:146-50; discussion 150-1. [PMID: 12565772 DOI: 10.1016/s0302-2838(02)00555-9] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
INTRODUCTION AND OBJECTIVES A problem in the interpretation of noninvasive urine tests for detection of bladder carcinoma is the finding of false-positive results. Several authors have described that patients with false-positive results are at high risk for tumor recurrence or progression. Only few data are available for comparing the clinical course of patients with false-positive test results and patients with true-negative results. We studied whether patients with false-positive results of various urine test had a higher recurrence rate than patients with true-negative results. METHODS Urine samples from 61 patients without evidence of active bladder carcinoma were included. Of the 61 patients, 51 had a history of bladder cancer, and 10 underwent transurethral resection for suspect of bladder carcinoma but had negative pathologic findings. Immunocytology (Lewis X and 486p3/12) was performed on bladder washings, and BTAstat and NMP22 were performed on urine samples. RESULTS During the follow-up period, 22 patients had one or more false-positive BTAstat test results, 25 patients had one or more false-positive NMP22 tests, 42 patients had at least one false-positive Lewis X test, and 11 patients had one or more false-positive 486p3/12 test. During a follow-up period of 3-39 months (median, 17.6 months) four patients expected a tumor recurrence. Among patients with false-positive urine test results 2 of 22 (9.1%, BTAstat), 2 of 25 (8%, NMP22), 4 of 42 (9.5%, Lewis X), and 3 of 11 (27.2%, 486p3/12) suffered from tumor recurrence. In contrast, among patients with true-negative test results 2 of 39 (5.2%, BTAstat), 2 of 36 (5.6%, NMP22), 0 of 18 (0%, Lewis X), 1 of 50 (2.0%, 486p3/12) had a tumor recurrence. CONCLUSIONS Patients with a false-positive urine test result do not generally have a greater risk of tumor recurrence or progression than patients with a true-negative result. In our series, only patients with false-positive 486p3/12 test result had a higher recurrence rate. Our findings do not justify a more aggressive adjuvant treatment or surveillance for patients with false-positive urine tests.
Collapse
Affiliation(s)
- Martin G Friedrich
- University Hospital Eppendorf, Department of Urology, University of Hamburg, Martinistrasse 52, D-20246, Hamburg, Germany.
| | | | | | | | | |
Collapse
|
9
|
FRIEDRICH MARTING, HELLSTERN ANGELIKA, HAUTMANN STEFANH, GRAEFEN MARKUS, CONRAD STEFAN, HULAND EDITH, HULAND HARTWIG. Clinical use of Urinary Markers For The Detection And Prognosis Of Bladder Carcinoma:. J Urol 2002. [DOI: 10.1097/00005392-200208000-00014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Friedrich MG, Hellstern A, Hautmann SH, Graefen M, Conrad S, Huland E, Huland H. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests. J Urol 2002; 168:470-4. [PMID: 12131290 DOI: 10.1016/s0022-5347(05)64660-5] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
PURPOSE The noninvasive detection of urothelial carcinoma remains challenging. We prospectively evaluated urine markers for bladder carcinoma. We compared the NMP22 (Matritech, Cambridge, Massachusetts) and BTA Stat (Bard Diagnostics, Redmond, Washington) tests with immunocytology using mAbs 486p3/12 and BG7 against Lewis X antigen. MATERIALS AND METHODS The NMP22 and BTA Stat tests were performed in urine samples and immunocytology with mAbs 486p3/12 and BG7 staining were performed in bladder washing specimens in 146 samples of 115 patients undergoing transurethral resection for suspected bladder carcinoma (70) or 45 undergoing followup cystoscopy for a history of bladder carcinoma (76). Bladder carcinoma was detected in 54 patients, including stages pTa in 25, pT1 in 20, pT2 in 8 and carcinoma in situ in 1, while 61 had no evidence of bladder carcinoma. The cutoff was 10 units per ml. for the NMP22, 30% positive cells for 486p3/12 and 5% positive cells for the Lewis X tests. RESULTS BTA Stat was positive in 65 samples (44.5%) and NMP22 was positive in 69 (47.3%). Immunocytology with mAbs 486p3/12 and BG7 against Lewis X was positive in 52 (35.6%) and 109 (74.7%) samples, respectively. Sensitivity was 70.3% for BTA Stat, 68.5% for NMP22, 68.5% for 486p3/12 and 94.4% for Lewis X. Specificity was 70.6% for BTA Stat, 65.2% for NMP22, 83.6% for 486p3/12 and 36.9% for Lewis X. Area under the receiver operating characteristics curve was 0.6804 for NMP22, 0.7226 for Lewis X and 0.8002 for 486p3/12. False-positive results on BTA Stat in 2 of 22 patients (9%), on NMP22 in 2 of 25 (8%), on 486p3/12 in 3 of 11 (27%) and on Lewis X in 4 of 43 (9.3%) were associated with tumor recurrence. Furthermore, negative results on BTA Stat in 2 of 39 patients (2%), on NMP22 in 2 of 36 (0.5%), on Lewis X in 0 of 18 (0%) and on 486p3/12 in 1 of 50 (2%) was associated with tumor recurrence during followup. CONCLUSIONS Immunocytology with mAbs against Lewis X showed higher sensitivity than all commercially available tests evaluated. Because of its high sensitivity and high negative predictive value, it may be useful for screening in a high risk population. Patients with a false-positive 486p3/12 test results are at increased risk for tumor recurrence compared with those with negative results.
Collapse
Affiliation(s)
- Martin G Friedrich
- Department of Urology, University Hospital, University of Hamburg, Hamburg, Germany
| | | | | | | | | | | | | |
Collapse
|
11
|
A Comparison of BTA Stat, Hemoglobin Dipstick, Telomerase and Vysis Urovysion Assays for the Detection of Urothelial Carcinoma in Urine. J Urol 2002. [DOI: 10.1097/00005392-200205000-00015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
12
|
Lipinski M, Jeromin L. Comparison of the bladder tumour antigen test with photodynamic diagnosis in patients with pathologically confirmed recurrent superficial urinary bladder tumours. BJU Int 2002; 89:757-9. [PMID: 11966640 DOI: 10.1046/j.1464-410x.2002.02717.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To verify the sensitivity of the bladder tumour antigen (BTAstat, Bard Urological, Covington, GA) test against the sensitive procedure of photodynamic diagnosis (PDD), in which 5-aminolaevulinic acid (5-ALA, a precursor of fluorescent porphyrins) is absorbed by the tumour and detected by ultraviolet cystoscopy, in the early diagnosis of urinary bladder tumours. PATIENTS AND METHODS Forty-three patients (31 men and 12 women, age range 21-87 years) were assessed after transurethral resection of their bladder tumour using the BTAstat test and PDD. Sixty-nine biopsies from suspect areas of bladder mucosa were taken during cystoscopy under ultraviolet light and all suspect lesions electrocoagulated. RESULTS Thirty-five patients (81%) had a positive BTAstat test; in these patients PDD detected malignant lesions (17 Ta1G1-2, two T1G2, two T1G3 and 14 Tis). In eight patients (19%) the BTAstat was negative but PDD detected three malignant lesions (two Tis and one TaG1). CONCLUSIONS PDD is valuable for detecting bladder malignancy and can identify small lesions not detected by the BTAstat test.
Collapse
Affiliation(s)
- M Lipinski
- Clinic of Urology, Medical University of Lodz, Pabianicka 62, 93-513 Lodz, Poland.
| | | |
Collapse
|
13
|
HALLING KEVINC, KING WALTER, SOKOLOVA IRINAA, KARNES RJEFFREY, MEYER REIDG, POWELL ERICL, SEBO THOMASJ, CHEVILLE JOHNC, CLAYTON AMYC, KRAJNIK KELLYL, EBERT THOMASA, NELSON ROBERTE, BURKHARDT HALEHM, RAMAKUMAR SANJAY, STEWART CHRISTOPHERS, PANKRATZ VERNONS, LIEBER MICHAELM, BLUTE MICHAELL, ZINCKE HORST, SEELIG STEVENA, JENKINS ROBERTB, O’KANE DENNISJ. A Comparison of BTA Stat, Hemoglobin Dipstick, Telomerase and Vysis Urovysion Assays for the Detection of Urothelial Carcinoma in Urine. J Urol 2002. [DOI: 10.1016/s0022-5347(05)65072-0] [Citation(s) in RCA: 133] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- KEVIN C. HALLING
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - WALTER KING
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - IRINA A. SOKOLOVA
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - R. JEFFREY KARNES
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - REID G. MEYER
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - ERIC L. POWELL
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - THOMAS J. SEBO
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - JOHN C. CHEVILLE
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - AMY C. CLAYTON
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - KELLY L. KRAJNIK
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - THOMAS A. EBERT
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - ROBERT E. NELSON
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - HALEH M. BURKHARDT
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - SANJAY RAMAKUMAR
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - CHRISTOPHER S. STEWART
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - VERNON S. PANKRATZ
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - MICHAEL M. LIEBER
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - MICHAEL L. BLUTE
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - HORST ZINCKE
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - STEVEN A. SEELIG
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - ROBERT B. JENKINS
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - DENNIS J. O’KANE
- From the Departments of Laboratory Medicine and Pathology, Urology and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| |
Collapse
|
14
|
Abstract
Cystoscopy is currently considered the gold standard for the detection of bladder tumors. The role of urine cytology in the initial detection and follow-up of patients is under discussion. New elaborative and rapid assays are available that may circumvent the low sensitivity and poor reproducibility of urine cytology. The methods that have been tested extensively are the nuclear matrix protein (NMP22) assay, the BTA stat assay, and the BTA TRAK enzyme-linked immunosorbent assay. Both outperform cytology in the detection of low-grade lesions. The specificity of both assays, however, lags behind that of cytology. The data from retrospective analyses are insufficient to justify clinical integration, and the need to replace cystoscopy with these novel assays remains to be proven.
Collapse
Affiliation(s)
- H G van der Poel
- Department of Urology, Antoni van Leeuwenhoek Hospital/NKI, Amsterdam, The Netherlands.
| | | |
Collapse
|
15
|
De Dominicis C, Liberti M, Perugia G, De Nunzio C, Sciobica F, Zuccalà A, Sarkozy A, Iori F. Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder cancer: improvement in diagnostic sensitivity. Urology 2001; 57:1059-62. [PMID: 11377304 DOI: 10.1016/s0090-4295(01)00948-7] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVES To use 5-aminolevulinic acid (5-ALA) in diagnostic cystoscopy and during transurethral resection of the bladder (TURB) to treat transitional cell carcinoma. The efficacy of this new technique was compared with standard cystoscopy. METHODS The 5-ALA, instilled in the bladder 2 hours before cystoscopy, makes the pathologic tissue fluorescent when illuminated with blue light (375 to 400 nm). This allows a better recognition of the neoplastic forms for both diagnostic and therapeutic purposes during TURB. This method has been used since May 1997 on 49 patients in whom bladder tumor was diagnosed either immediately or during postchemotherapy follow-up. RESULTS One hundred seventy-nine biopsies were taken of fluorescent and nonfluorescent areas (3.5 per patient) to check the effectiveness of the new method compared with standard cystoscopy. A good correlation was found between 5-ALA cystoscopy and the histopathologic diagnosis, with a good sensitivity (87%). The 5-ALA cystoscopy allowed the diagnosis of a tumor in 24 patients with negative standard cystoscopic findings. Furthermore, 5-ALA cystoscopy detected 7 cases of carcinoma in situ. Neither local nor systemic (because of endovesical instillation) side effects were noted. CONCLUSIONS We believe that 5-ALA could be routinely used in the diagnosis of superficial bladder tumors, as it was shown to improve the diagnostic sensitivity for carcinoma in situ and to reduce the risk of recurrence related to missed cancerous lesions or incomplete TURB.
Collapse
Affiliation(s)
- C De Dominicis
- Dipartimento di Urologia U. Bracci, Università di Roma La Sapienza,, Rome, Italy
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Ishiwata S, Takahashi S, Homma Y, Tanaka Y, Kameyama S, Hosaka Y, Kitamura T. Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 2001; 57:811-5. [PMID: 11306420 DOI: 10.1016/s0090-4295(00)01074-8] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES To investigate the clinical utility of fluorescence in situ hybridization (FISH) of voided urine in the detection of bladder cancer and the prediction of its recurrence. METHODS FISH with centromere-specific probes for chromosomes 9 and 17 was performed to evaluate the chromosomal alterations of exfoliated urothelial cells in voided urine obtained from 44 patients with bladder cancer and 20 controls. The analysis was also performed in 17 patients with bladder cancer after complete transurethral resection to prospectively determine whether FISH can predict tumor recurrence. RESULTS The sensitivity to detect bladder cancer by FISH analysis (85%) was significantly higher than that by urine cytologic examination (32%) and by the bladder tumor antigen test (64%) (P <0.0001 and P = 0.026, respectively). The specificity of FISH, cytologic analysis, and the bladder tumor antigen test was 95%, 100%, and 80%, respectively. Among the 17 patients tested after transurethral resection, 7 of 13 FISH-positive patients developed tumor recurrence within the 27-month follow-up period; none of 4 FISH-negative patients developed recurrence during the same period. The recurrence rate in patients with the loss of chromosome 17 was 100%, significantly higher than the 23% for patients without this alteration (P = 0.015). CONCLUSIONS These findings suggest that FISH analysis of exfoliated urothelial cells in voided urine can efficiently detect bladder cancer and predict its recurrence.
Collapse
Affiliation(s)
- S Ishiwata
- Department of Urology, University of Tokyo Faculty of Medicine, Tokyo, Japan
| | | | | | | | | | | | | |
Collapse
|
17
|
Gutiérrez Baños JL, del Henar Rebollo Rodrigo M, Antolín Juárez FM, García BM. Usefulness of the BTA STAT Test for the diagnosis of bladder cancer. Urology 2001; 57:685-9. [PMID: 11306381 DOI: 10.1016/s0090-4295(00)01090-6] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVES To evaluate the usefulness of the Bard BTA stat Test in the diagnosis and follow-up of bladder cancer and to compare this test to cytologic analysis and cystoscopy, routine diagnostic methods. METHODS Three hundred seventy-nine patients being followed up because of bladder cancer or with symptoms suggestive of bladder cancer underwent cystoscopy, cytologic analysis, and the BTA stat Test using a recently voided urine sample. In suspected cases, transurethral resection and histopathologic analysis were performed. RESULTS Of the 379 patients, 235 proved to have bladder cancer and 144 did not. The sensitivity was 73.62% for the BTA stat, 61.70% for cytologic examination, and 99.57% for cystoscopy. The specificity was 83.33% for the BTA stat, 92.36% for cytologic analysis, and 85.42% for cystoscopy. The BTA stat Test's sensitivity for grades 1, 2, and 3 tumor was 47.27%, 69.15%, and 95.35%, respectively. The sensitivity of cytologic analysis was 30.91%, 55.32%, and 88.37%. The BTA stat Test's sensitivity for stage was 45.65% in Stage Ta, 75.52% in T1, and 95.56% in Stage T2-4; the cytologic results were 28.26%, 65.03%, and 84.44%, respectively. The combination of both tests improved the sensitivity and decreased the specificity slightly. CONCLUSIONS The high sensitivity of the BTA stat Test, together with the data obtained from the parameters used for the evaluation of the test, demonstrate the better results of the BTA stat Test compared with cytologic analysis, making it a thoroughly valid diagnostic tool in the diagnosis of bladder cancer. In our opinion, the BTA stat Test can replace the use of cytologic analysis in the diagnosis of bladder cancer, but not the use of cystoscopy.
Collapse
Affiliation(s)
- J L Gutiérrez Baños
- Department of Urology, "Marqués de Valdecilla" University Hospital, Santander, Spain
| | | | | | | |
Collapse
|
18
|
Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright Jr. GL. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. THE AMERICAN JOURNAL OF PATHOLOGY 2001; 158:1491-502. [PMID: 11290567 PMCID: PMC1891900 DOI: 10.1016/s0002-9440(10)64100-4] [Citation(s) in RCA: 326] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Development of noninvasive methods for the diagnosis of transitional cell carcinoma (TCC) of the bladder remains a challenge. A ProteinChip technology (surface enhanced laser desorption/ionization time of flight mass spectrometry) has recently been developed to facilitate protein profiling of biological mixtures. This report describes an exploratory study of this technology as a TCC diagnostic tool. Ninety-four urine samples from patients with TCC, patients with other urogenital diseases, and healthy donors were analyzed. Multiple protein changes were reproducibly detected in the TCC group, including five potential novel TCC biomarkers and seven protein clusters (mass range, 3.3 to 133 kd). One of the TCC biomarkers (3.4 kd) was also detected in bladder cancer cells procured from bladder barbotage and was identified as defensin. The TCC detection rates provided by the individual markers ranged from 43 to 70% and specificities from 70 to 86%. Combination of the protein biomarkers and clusters, increased significantly the sensitivity for detecting TCC to 87% with a specificity of 66%. Interestingly, this combinatorial approach provided sensitivity of 78% for detecting low-grade TCC compared to only 33% of voided urine or bladder-washing cytology. Collectively these results support the potential of this proteomic approach for the development of a highly sensitive urinary TCC diagnostic test.
Collapse
Affiliation(s)
| | | | - Savvas Mendrinos
- Eastern Virginia Medical School, Norfolk; and the Virginia Prostate Center,§
| | - Keyur Patel
- Eastern Virginia Medical School, Norfolk; and the Virginia Prostate Center,§
| | | | | | - Suhail Nasim
- Eastern Virginia Medical School, Norfolk; and the Virginia Prostate Center,§
| | | |
Collapse
|
19
|
Abstract
PURPOSE A number of urine based markers have been and are being investigated for the diagnosis and prognostication of urological conditions. A majority of these markers have been evaluated in urological neoplasms, particularly bladder cancer. The diagnosis of bladder cancer currently relies on identifying malignant cells in the urine and subsequently visualizing the tumor on cystoscopy. This diagnosis is further confirmed by transurethral resection or biopsy. While urine cytology is specific, it is not sensitive, especially for detecting low grade disease. This characteristic has prompted the search for more accurate markers of bladder cancer. In this review we critically examine the results of studies evaluating various markers for bladder cancer. MATERIALS AND METHODS The published literature on urine based markers for all urological diseases, particularly bladder cancer, was identified using a MEDLINE search and critically analyzed. The sensitivity, specificity, positive and negative predictive values of the various markers were compared. The benefit of using combined markers rather than a single marker was also analyzed from published reports. RESULTS Most published literature on urine based markers for urological malignancies involve such markers for diagnosing and prognosticating bladder cancer. Hence, we focused mainly on urine based markers in bladder cancer. Most markers appear to have an advantage over urine cytology in terms of sensitivity, especially for detecting low grade, superficial tumors. However, most markers tend to be less specific than cytology, yielding more false-positive results. This scenario is more common in patients with concurrent bladder inflammation or other benign bladder conditions. However, there is reason to be optimistic about several new markers that appear to provide better specificity. Few urine based markers have been identified and investigated in other urological tumors. CONCLUSIONS Detecting bladder cancer using diagnostic markers still presents a challenge. A number of new markers are currently available that appear to be significantly more accurate than cytology. However, further studies involving a larger number of patients are required to determine their accuracy and widespread applicability for diagnosing bladder cancer. Urine based markers do not appear to have a significant role in the diagnosis or prognosis of other urological malignancies, such as prostate, kidney or testicular cancer.
Collapse
Affiliation(s)
- B R Konety
- Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | | |
Collapse
|
20
|
Abstract
In this subject review, a series of morphology-based and molecular markers were compared with urinary cytology for the detection of recurrent urothelial neoplasia. Among the various biomarkers reviewed, the average published sensitivity and specificity for the Bard BTA test was 60% and 77%; the NMP22 Test was 67% and 72%; the telomerase assay was 77% and 85%; and the microsatellite assay was 89% and 100%. DNA ploidy measurements and immunoassays designed to detect keratins, proteins, hyaluronidase, growth factors, cell adhesion molecules, fibrinogen degradation products, cell cycle regulators, and molecular markers were also included. Although the performance features of these biomarkers have varied and the cytologic methods to which they have been compared have not been standardized, several of the procedures have received considerable support from urologists as assisting them in the management of their patients.
Collapse
Affiliation(s)
- J S Ross
- Department of Pathology and Labortory Medicine, Albany Medical College, Albany, New York 12208, USA.
| | | |
Collapse
|
21
|
HALLING KEVINC, KING WALTER, SOKOLOVA IRINAA, MEYER REIDG, BURKHARDT HALEHM, HALLING AMYC, CHEVILLE JOHNC, SEBO THOMASJ, RAMAKUMAR SANJAY, STEWART CHRISTOPHERS, PANKRATZ SHANE, O’KANE DENNISJ, SEELIG STEVENA, LIEBER MICHAELM, JENKINS ROBERTB. A COMPARISON OF CYTOLOGY AND FLUORESCENCE IN SITU HYBRIDIZATION FOR THE DETECTION OF UROTHELIAL CARCINOMA. J Urol 2000. [DOI: 10.1016/s0022-5347(05)67104-2] [Citation(s) in RCA: 261] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- KEVIN C. HALLING
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - WALTER KING
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - IRINA A. SOKOLOVA
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - REID G. MEYER
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - HALEH M. BURKHARDT
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - AMY C. HALLING
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - JOHN C. CHEVILLE
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - THOMAS J. SEBO
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - SANJAY RAMAKUMAR
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - CHRISTOPHER S. STEWART
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - SHANE PANKRATZ
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - DENNIS J. O’KANE
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - STEVEN A. SEELIG
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - MICHAEL M. LIEBER
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| | - ROBERT B. JENKINS
- From the Departments of Laboratory Medicine and Pathology, Urology, and Biostatistics, Mayo Clinic and Foundation, Rochester, Minnesota, and Vysis, Inc., Downers Grove, Illinois
| |
Collapse
|
22
|
Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000; 2:116-23. [PMID: 11229514 PMCID: PMC1906906 DOI: 10.1016/s1525-1578(10)60625-3] [Citation(s) in RCA: 229] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
The purpose of this study was to develop a multitarget, multicolor fluorescence in situ hybridization (FISH) assay for the detection of urothelial carcinoma (UC) in urine specimens. Urinary cells obtained from voided urine specimens of 21 patients with UC and 9 normal donors were analyzed with nine different centromere enumeration probes and a single locus-specific indicator probe to determine an optimal set of FISH probes for UC detection. The four probes with the greatest sensitivity for UC detection were then labeled with a unique fluorophore and combined into a single probe set. The probes with the greatest combined sensitivity for UC detection were CEP3, CEP7, CEP17, and the 9p21 (P16) LSI. This probe set was used to evaluate urine specimens acquired from 179 patients for prospective testing (46 with biopsy-proven UC). FISH slides were evaluated by scanning the slide for cells with nuclear features suggestive of malignancy and assessing the FISH signal pattern of these cells for polysomy (ie, gains of two or more different chromosomes). A receiver operator characteristic curve revealed that a cutoff of 5 cells with polysomy as the positive criterion for cancer resulted in an overall sensitivity of 84.2% for patients with biopsy-proven UC and a specificity of 91.8% among patients with genitourinary disorders but no evidence of UC. This study demonstrates that a multitarget, multicolor FISH assay containing centromeric probes to chromosomes 3, 7, and 17 and a locus-specific probe to band 9p21 has high sensitivity and specificity for the detection of UC in voided urine specimens.
Collapse
|
23
|
|
24
|
Malkowicz SB. The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol Clin North Am 2000; 27:63-73, ix. [PMID: 10696246 DOI: 10.1016/s0094-0143(05)70235-4] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The BTA TRAK assay is a quantitative sandwich format enzyme immunoassay performed in a reference laboratory. It measures levels of human complement factor H-related protein (hCFHrp) which is similar to human complement factor H. Test characteristics reveal an overall sensitivity of 68% to 77.5% and a specificity of 50%-75%. Retrospective analysis of urine specimens employing hazard analysis suggests that BTA TRAK may have a role as a quantitative diagnostic marker in monitoring bladder cancer patients. Prospective studies are required to validate this application and other uses of the BTA TRAK assay in the management of bladder cancer patients.
Collapse
Affiliation(s)
- S B Malkowicz
- Division of Urology, University of Pennsylvania School of Medicine, Philadelphia, USA
| |
Collapse
|
25
|
Lokeshwar VB, Obek C, Pham HT, Wei D, Young MJ, Duncan RC, Soloway MS, Block NL. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 2000; 163:348-56. [PMID: 10604388 DOI: 10.1016/s0022-5347(05)68050-0] [Citation(s) in RCA: 164] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
PURPOSE Specific patterns of progression and frequent recurrence of bladder tumors determine the choice of treatment, frequency of surveillance, quality of life, and ultimately, patient prognosis. The prognosis would be improved if an accurate noninvasive test was available for diagnosis. Identification of markers that function in bladder cancer progression would be helpful in designing such diagnostic tests. The glycosaminoglycan, hyaluronic acid (HA), promotes tumor metastasis. Hyaluronidase (HAase), an endoglycosidase, degrades HA into small fragments that promote angiogenesis. We have previously shown that both HA and HAase are associated with bladder cancer and may function in bladder tumor angiogenesis. In this study we examined whether urinary HA and HAase levels serve as bladder cancer markers. MATERIALS AND METHODS Among the 513 urine specimens analyzed, 261 were from transitional cell carcinoma (TCC) patients, 9 from patients with non-TCC tumors, and 243 from controls (normals, patients with other genitourinary (GU) conditions or a history of bladder cancer (HxBCa)). The urinary HA and HAase levels were measured by two ELISA-like assays that utilize a biotinylated HA binding protein for detection. These levels were normalized to total urinary protein and were expressed as ng./mg. (HA test) and mU/mg. (HAase test), respectively. RESULTS The urinary HA levels were elevated (2.5 to 6.5 fold) in bladder cancer patients (1173.7+/-173.4; n = 261) as compared with normals (246.1+/-38.5; n = 41); GU patients (306.6+/-32.2; n = 133), and patients with a HxBCa (351.1+/-49.1; n = 69) (p <0.001). The urinary HAase levels were elevated (3 to 7 fold) in G2/G3 bladder cancer patients (26.2+/-3.2) as compared with normals (4.5+/-0.9) and patients with either GU conditions (5.8+/-1.3), HxBCa (8.2+/-2.6) or G1 tumors (9.7+/-2.5) (p <0.001). The HA test showed 83.1% sensitivity, 90.1% specificity and 86.5% accuracy in detecting bladder cancer, regardless of the tumor grade. The HAase test showed 81.5% sensitivity, 83.8% specificity and 82.9% accuracy to detect G2/G3 patients. Combining the inferences of the HA and HAase tests (HA-HAase test) resulted in detection of bladder cancer, regardless of tumor grade and stage, with higher sensitivity (91.2%) and accuracy (88.3%), and comparable specificity (84.4%). CONCLUSION Our results show that the HA-HAase urine test is a noninvasive, highly sensitive and specific method for detecting bladder cancer and evaluating its grade.
Collapse
Affiliation(s)
- V B Lokeshwar
- Department of Urology, University of Miami School of Medicine, Florida, USA
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
Bladder tumor antigen, nuclear matrix protein 22, telomerase activity, fibrin degradation products assay, and a number of diagnostic tests on exfoliated urethelial cells are being tried to replace or decrease the frequency of cystoscopies. The results of these studies have shown that although some of these tests are promising, the standard of care for patients with hematuria or previously treated bladder carcinoma is still cystoscopy. New and non-invasive tests are on the horizon, however. It is essential to find accurate prognostic factors in patients with T1 disease which will predict the cases which will progress to muscle invasive disease. It has been clearly shown that the depth of invasion within the submucosa is closely related with survival. It has been established that continent diversions improve the quality of life in patients who have undergone cystectomy. Furthermore, this type of diversion was shown to improve survival. This fact can be attributed to early cystectomy which was prompted by the increased patient acceptance.
Collapse
Affiliation(s)
- H Ozen
- Department of Urology, Hacettepe University, Ankara, Turkey
| |
Collapse
|